TLRY Quote, Financials, Valuation and Earnings

Edesa Biotech has a net margin of -424.93% compared to Tilray Brands's net margin of --. Tilray Brands's return on equity of -28.79% beat Edesa Biotech's return on equity of --.

Tilray Brands has a consensus price target of $1.31, signalling upside risk potential of 165.32%. On the other hand Edesa Biotech has an analysts' consensus of $19.00 which suggests that it could grow by 708.51%. Given that Edesa Biotech has higher upside potential than Tilray Brands, analysts believe Edesa Biotech is more attractive than Tilray Brands.

Tilray Brands has a beta of 1.885, which suggesting that the stock is 88.482% more volatile than S&P 500. In comparison Edesa Biotech has a beta of 0.603, suggesting its less volatile than the S&P 500 by 39.713%.

Tilray Brands has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tilray Brands pays -- of its earnings as a dividend. Edesa Biotech pays out -- of its earnings as a dividend.

Tilray Brands quarterly revenues are $185.8M, which are larger than Edesa Biotech quarterly revenues of --. Tilray Brands's net income of -$789.4M is lower than Edesa Biotech's net income of -$1.6M. Notably, Tilray Brands's price-to-earnings ratio is -- while Edesa Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tilray Brands is 0.51x versus 23.24x for Edesa Biotech. Usually stocks with elevated PS ratios are considered overvalued.

ESSA Pharma has a net margin of -424.93% compared to Tilray Brands's net margin of --. Tilray Brands's return on equity of -28.79% beat ESSA Pharma's return on equity of --.

Tilray Brands has a consensus price target of $1.31, signalling upside risk potential of 165.32%. On the other hand ESSA Pharma has an analysts' consensus of $1.68 which suggests that it could fall by -6.6%. Given that Tilray Brands has higher upside potential than ESSA Pharma, analysts believe Tilray Brands is more attractive than ESSA Pharma.

Tilray Brands has a beta of 1.885, which suggesting that the stock is 88.482% more volatile than S&P 500. In comparison ESSA Pharma has a beta of 1.609, suggesting its more volatile than the S&P 500 by 60.943%.

Tilray Brands has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ESSA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tilray Brands pays -- of its earnings as a dividend. ESSA Pharma pays out -- of its earnings as a dividend.

Tilray Brands quarterly revenues are $185.8M, which are larger than ESSA Pharma quarterly revenues of --. Tilray Brands's net income of -$789.4M is lower than ESSA Pharma's net income of -$8.5M. Notably, Tilray Brands's price-to-earnings ratio is -- while ESSA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tilray Brands is 0.51x versus -- for ESSA Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience has a net margin of -424.93% compared to Tilray Brands's net margin of -1559.32%. Tilray Brands's return on equity of -28.79% beat Lexaria Bioscience's return on equity of -118.15%.

Tilray Brands has a consensus price target of $1.31, signalling upside risk potential of 165.32%. On the other hand Lexaria Bioscience has an analysts' consensus of $7.00 which suggests that it could grow by 314.2%. Given that Lexaria Bioscience has higher upside potential than Tilray Brands, analysts believe Lexaria Bioscience is more attractive than Tilray Brands.

Tilray Brands has a beta of 1.885, which suggesting that the stock is 88.482% more volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 0.855, suggesting its less volatile than the S&P 500 by 14.5%.

Tilray Brands has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tilray Brands pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.

Tilray Brands quarterly revenues are $185.8M, which are larger than Lexaria Bioscience quarterly revenues of $174K. Tilray Brands's net income of -$789.4M is lower than Lexaria Bioscience's net income of -$2.7M. Notably, Tilray Brands's price-to-earnings ratio is -- while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tilray Brands is 0.51x versus 51.21x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals has a net margin of -424.93% compared to Tilray Brands's net margin of --. Tilray Brands's return on equity of -28.79% beat Xenon Pharmaceuticals's return on equity of --.

Tilray Brands has a consensus price target of $1.31, signalling upside risk potential of 165.32%. On the other hand Xenon Pharmaceuticals has an analysts' consensus of $57.31 which suggests that it could grow by 50.03%. Given that Tilray Brands has higher upside potential than Xenon Pharmaceuticals, analysts believe Tilray Brands is more attractive than Xenon Pharmaceuticals.

Tilray Brands has a beta of 1.885, which suggesting that the stock is 88.482% more volatile than S&P 500. In comparison Xenon Pharmaceuticals has a beta of 1.212, suggesting its more volatile than the S&P 500 by 21.24%.

Tilray Brands has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tilray Brands pays -- of its earnings as a dividend. Xenon Pharmaceuticals pays out -- of its earnings as a dividend.

Tilray Brands quarterly revenues are $185.8M, which are larger than Xenon Pharmaceuticals quarterly revenues of --. Tilray Brands's net income of -$789.4M is lower than Xenon Pharmaceuticals's net income of -$65.7M. Notably, Tilray Brands's price-to-earnings ratio is -- while Xenon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tilray Brands is 0.51x versus 225.92x for Xenon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.